drugset / Trial / NCT00060554

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

NCT00060554

Phase 2 Withdrawn 300 enrolled Schering-Plough
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and heparin are drugs that inhibit blood clotting.

Timeline

Start
2003-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified
Subject Heparin Other / unclassified